- Home
- UROY vs INBX Comparison
UROY vs INBX Comparison
Compare UROY & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UROY | INBX |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2026 | 2024 |
Fundamental Metrics
Financial Performance| Metric | UROY | INBX |
|---|---|---|
| Price | $4.14 | $124.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | ★ 2.4M | 243.1K |
| Earning Date | 03-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 825.00 | N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $186,807,000.00 | $1,300,000.00 |
| Revenue This Year | $279.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.52 | ★ N/A |
| Revenue Growth | ★ 1565.99 | 550.00 |
| 52 Week Low | $2.56 | $26.19 |
| 52 Week High | $5.52 | $155.29 |
Technical Indicators
Market Signals| Indicator | UROY | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 61.03 | 68.97 |
| Support Level | $3.54 | $72.39 |
| Resistance Level | $4.48 | $153.14 |
| Average True Range (ATR) | 0.20 | 8.68 |
| MACD | -0.04 | 2.83 |
| Stochastic Oscillator | 49.14 | 80.96 |
Price Performance
Historical ComparisonAbout UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.